Lars Dyrskjot
Overview
Explore the profile of Lars Dyrskjot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
8424
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prip F, Lamy P, Lindskrog S, Strandgaard T, Nordentoft I, Birkenkamp-Demtroder K, et al.
Nat Genet
. 2025 Jan;
57(1):115-125.
PMID: 39753772
Understanding the molecular landscape of nonmuscle-invasive bladder cancer (NMIBC) is essential to improve risk assessment and treatment regimens. We performed a comprehensive genomic analysis of patients with NMIBC using whole-exome...
2.
Lobo N, Duan Z, Sood A, Zhao H, Lindskrog S, Dyrskjot L, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39448349
The impact of sex on non-muscle-invasive bladder cancer (NMIBC) remains uncertain and current evidence is conflicting. To address this uncertainty, we conducted an integrative analysis using Surveillance, Epidemiology and End...
3.
Frydendahl A, Nors J, Rasmussen M, Henriksen T, Nesic M, Reinert T, et al.
Eur J Cancer
. 2024 Sep;
211:114314.
PMID: 39316995
Introduction: Circulating tumor (ctDNA) can be used to detect residual disease after cancer treatment. Detecting low-level ctDNA is challenging, due to the limited number of recoverable ctDNA fragments at any...
4.
Wyatt A, Litiere S, Bidard F, Cabel L, Dyrskjot L, Karlovich C, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5034-5041.
PMID: 39269996
Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The RECIST guidelines based on repeat cancer imaging are widely adopted in...
5.
Korner S, Tolbod L, Pedersen B, Boellaard T, Milling R, Brandt S, et al.
J Clin Med
. 2024 Aug;
13(16).
PMID: 39200797
Accurate assessment of therapy response to chemotherapy could possibly offer a bladder-sparing approach in selected patients with localized muscle-invasive bladder cancer (MIBC). The aim of this study was to evaluate...
6.
Okholm T, Kamstrup A, Nielsen M, Hollensen A, Graversgaard M, Sorensen M, et al.
Elife
. 2024 Jul;
13.
PMID: 39041323
Circular RNAs represent a class of endogenous RNAs that regulate gene expression and influence cell biological decisions with implications for the pathogenesis of several diseases. Here, we disclose a novel...
7.
Roghmann F, Goebell P, Dyrskjot L, van Rhijn B, Kafferlein H, Hakenberg O, et al.
Bladder Cancer
. 2024 Jul;
8(1):1-4.
PMID: 38994515
Marker research, and in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing...
8.
Hof J, Vermeulen S, van der Heijden A, Verhaegh G, Dyrskjot L, Catto J, et al.
Bladder Cancer
. 2024 Jul;
9(1):59-71.
PMID: 38994482
Background: Various germline genetic variants are associated with the prognosis of non-muscle invasive bladder cancer (NMIBC). Germline variants in genes frequently somatically mutated in bladder cancer have not been studied...
9.
Lindskrog S, Dyrskjot L
Transl Androl Urol
. 2024 Jul;
13(6):1056-1060.
PMID: 38983478
No abstract available.
10.
Nordentoft I, Lindskrog S, Birkenkamp-Demtroder K, Gonzalez S, Kuzman M, Levatic J, et al.
Eur Urol
. 2024 May;
86(4):301-311.
PMID: 38811314
Background And Objective: Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability of detecting ctDNA in settings of low tumor burden...